940,831 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Purchased by Great Point Partners LLC

Great Point Partners LLC purchased a new position in TScan Therapeutics, Inc. (NASDAQ:TCRX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 940,831 shares of the company’s stock, valued at approximately $5,504,000. TScan Therapeutics comprises approximately 1.1% of Great Point Partners LLC’s holdings, making the stock its 26th largest position. Great Point Partners LLC owned 1.78% of TScan Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in shares of TScan Therapeutics during the 2nd quarter worth about $70,000. Pale Fire Capital SE raised its stake in TScan Therapeutics by 30.2% during the fourth quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock worth $126,000 after purchasing an additional 4,998 shares during the period. Cornercap Investment Counsel Inc. purchased a new position in TScan Therapeutics during the second quarter worth approximately $134,000. Cannon Global Investment Management LLC acquired a new position in shares of TScan Therapeutics in the 1st quarter valued at $139,000. Finally, Rhumbline Advisers purchased a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $274,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $5.20 on Tuesday. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. The company has a market cap of $274.89 million, a PE ratio of -4.06 and a beta of 0.79. The company’s fifty day simple moving average is $6.10 and its 200-day simple moving average is $7.05. TScan Therapeutics, Inc. has a 52 week low of $2.43 and a 52 week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. As a group, equities research analysts anticipate that TScan Therapeutics, Inc. will post -1.36 EPS for the current year.

Wall Street Analyst Weigh In

TCRX has been the topic of several research reports. Wedbush reaffirmed an “outperform” rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a report on Tuesday, August 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research note on Monday, August 12th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $12.00.

Insider Activity at TScan Therapeutics

In related news, Director Barbara Klencke purchased 5,000 shares of TScan Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares were purchased at an average cost of $5.69 per share, with a total value of $28,450.00. Following the transaction, the director now owns 35,000 shares of the company’s stock, valued at approximately $199,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were bought at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the purchase, the director now directly owns 35,000 shares of the company’s stock, valued at approximately $199,150. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares of the company’s stock, valued at $27,258.48. The disclosure for this sale can be found here. Company insiders own 2.76% of the company’s stock.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.